Fate Therapeutics (FATE) Change in Receivables (2018 - 2026)
Fate Therapeutics' (FATE) quarterly Change in Receivables came in at -$212000.0 in Q1 2026, up 81.31% YoY from -$116930.0 in Q1 2025, and down 190.99% on a QoQ basis from $233000.0 in Q4 2025.
Fate Therapeutics (FATE) Change in Receivables (2018 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 8 years of Change in Receivables data on file, last reported at -$212000.0 in Q1 2026.
- Quarterly Change in Receivables rose 81.31% year-over-year to -$212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 279.73% YoY) and the FY2025 annual result came in at -$2.6 million, down 335.76% from the prior year.
- Change in Receivables slipped to -$212000.0 in Q1 2026, from $233000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $28.3 million in Q4 2022 to a low of -$25.0 million in Q1 2023.
- A 5-year average of -$504294.1 and a median of -$713000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 1970.11% — and 2023, when it sank 1373.2%.
- Tracing FATE's Change in Receivables over 5 years: stood at $28.3 million in 2022, then tumbled by 98.98% to $288000.0 in 2023, then tumbled by 304.17% to -$588000.0 in 2024, then soared by 139.63% to $233000.0 in 2025, then sank by 190.99% to -$212000.0 in 2026.
- The last three Change in Receivables figures came in at -$212000.0 (Q1 2026), $233000.0 (Q4 2025), and -$713000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Jun 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.01 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Dec 31, 2024 | -588,000.00 |
| Dec 31, 2024 | -588,000.00 |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |